Inovio Pharmaceuticals

INO

Market cap $116M

Overview Fund Activity

2.18 USD

-0.10

4.39%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

2.20

+0.02

0.92%

1 day

-4.39%

5 days

-17.42%

1 month

14.74%

3 months

14.74%

6 months

3.32%

Year to date

19.78%

1 year

-67.85%

5 years

-98.84%

10 years

-97.62%

About: Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Employees: 134

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,384% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $94K

4% less funds holding

Funds holding: 107 [Q1] → 103 (-4) [Q2]

7% less capital invested

Capital invested by funds: $22.2M [Q1] → $20.7M (-$1.47M) [Q2]

9.36% less ownership

Funds ownership: 37.09% [Q1] → 27.72% (-9.36%) [Q2]

14% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 28

27% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 30

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

38% upside

Avg. target

$4

83% upside

High target

$5

129% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	$3	Neutral Reiterated	14 Aug 2025
Piper Sandler Edward Tenthoff	$5	Overweight Initiated	9 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about INO published over the past 30 days

Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 7:00 AM EDT Company Participants Jacqueline Shea - CEO, President & Director Conference Call Participants Katherine Degen Presentation Katherine Degen Good morning, and welcome to the H.C.

Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Zacks Investment Research

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa. , Aug. 26, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the FDA has notified INOVIO that it agrees with its rolling submission timeline for the BLA for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP.

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

PLYMOUTH MEETING, Pa. , Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C.

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jacqueline E. Shea - CEO, President & Director Jennie Willson - Corporate Participant Investor Relations - Corporate Participant Michael Sumner - Chief Medical Officer Peter D.

Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end Completed design verification (DV) testing of CELLECTRA® 5PSP device required for BLA submission and requested rolling submission from US Food and Drug Administration (FDA) Continuing to advance commercial preparations for potential launch of INO-3107 in 2026 if approved by FDA PLYMOUTH MEETING, Pa. , Aug. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2025 and provided an update on recent company developments.

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Zacks Investment Research

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1 Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year prior to receiving INO-3107 to 1.7 for Year 1 to 0.9 for Year 2 Partial data into the third 12-month period (Year 3 - median follow up 2.8 years following initial treatment) continued the trend of improvement and a reduced number of surgeries PLYMOUTH MEETING, Pa. , Aug. 11, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title "DNA Immunotherapy (INO-3107) Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP).

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Zacks Investment Research

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

PLYMOUTH MEETING, Pa. , Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025.

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

See News Rankings

Charts implemented using Lightweight Charts™